{"id":874,"date":"2026-10-26T10:07:34","date_gmt":"2026-10-26T08:07:34","guid":{"rendered":"https:\/\/www.pqra.gr\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/"},"modified":"2026-10-26T10:24:24","modified_gmt":"2026-10-26T08:24:24","slug":"indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/","title":{"rendered":"Indirect Treatment Comparisons Under the EU HTA Guidelines: What Will Be Accepted"},"content":{"rendered":"<p style=\"font-size:19px;line-height:1.7;color:#33414d;\"><strong>When no head-to-head trial exists, joint clinical assessment will still ask how your product compares. The methodological guidance adopted by the HTA Coordination Group sets out what evaluators expect, and it is more demanding than many developers assume.<\/strong><\/p>\n<h2>A gap that is common, not exceptional<\/h2>\n<p>Trials are usually designed for marketing authorisation, not for every comparator that Member States consider relevant. Indirect comparisons therefore sit at the centre of many assessments. The EU guidance on quantitative evidence synthesis was adopted on 8 March 2024, with further guidance on outcomes and on multiplicity, subgroup, sensitivity and post hoc analyses adopted on 10 June 2024.<\/p>\n<h2>Methods the guidance describes<\/h2>\n<p>The guidance covers several approaches, each with its own data needs.<\/p><ul><li><strong>Bucher adjusted indirect comparison<\/strong> for simple networks linked by a common comparator.<\/li><li><strong>Network meta-analysis<\/strong> where three or more interventions are connected.<\/li><li><strong>Matching-adjusted indirect comparison and simulated treatment comparison,<\/strong> which need individual patient data from at least one study.<\/li><li><strong>Anchored versus unanchored analyses:<\/strong> anchored analyses rest on randomised studies with a shared control; unanchored analyses, often built on single-arm data, rely on much stronger assumptions.<\/li><\/ul><p>The guidance does not prefer Bayesian over frequentist methods in principle; the choice must be justified by context.<\/p>\n<h2>What evaluators will look for<\/h2>\n<p>Acceptance depends on how well the analysis addresses bias rather than on the sophistication of the method. Populations must overlap sufficiently, effect modifiers must be identified and handled, and the potential bias in unanchored comparisons must be investigated and its impact assessed. Analyses and methods should be specified before the data are analysed, subgroup analyses need a prior rationale, and anything done after the fact must be labelled as post hoc.<\/p>\n<h2>Planning backwards from the dossier<\/h2>\n<p>The practical lesson is to decide on the comparison strategy early. Identify the comparators likely to be requested across Member States, check whether the trial populations can be aligned, and write the statistical analysis plan before results are known. Joint scientific consultation is an opportunity to test the approach while trial design can still change.<\/p>\n<h2>Common pitfalls to avoid<\/h2>\n<p>Several mistakes appear repeatedly when companies prepare comparisons late. The first is choosing the method because the data allow it rather than because the question requires it. The second is treating a matched analysis as if it removed all confounding, when it can only adjust for the factors that were measured. The third is reporting a single favourable result without showing how it changes under alternative assumptions.<\/p><p>A sound package presents the feasibility assessment first, explains why the studies can or cannot be compared, shows the sensitivity of results to key assumptions, and acknowledges residual uncertainty openly. Evaluators are more likely to give weight to an analysis that is candid about its limits than to one that claims certainty the data cannot support.<\/p>\n<h2>How PQRA helps<\/h2>\n<p>PQRA can help review your evidence package against the EU assessment framework, identify likely comparator gaps early, and coordinate the regulatory and market access perspectives so that evidence planning is consistent across both.<\/p>\n<p>If you are mapping your evidence strategy for joint clinical assessment,  <a href=\"\/el\/contact\/\"><strong>Contact PQRA<\/strong><\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>When no head-to-head trial exists, joint clinical assessment will still ask how your product compares. The methodological guidance adopted by the HTA Coordination Group sets out what evaluators expect, and it is more demanding than many developers assume. A gap that is common, not exceptional Trials are usually designed for marketing authorisation, not for every [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":970,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"saved_in_kubio":false,"_swpsp_post_exclude":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-874","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Indirect Treatment Comparisons Under the EU HTA Guidelines: What Will Be Accepted - PQRA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pqra.gr\/el\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/\" \/>\n<meta property=\"og:locale\" content=\"el_GR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Indirect Treatment Comparisons Under the EU HTA Guidelines: What Will Be Accepted - PQRA\" \/>\n<meta property=\"og:description\" content=\"When no head-to-head trial exists, joint clinical assessment will still ask how your product compares. The methodological guidance adopted by the HTA Coordination Group sets out what evaluators expect, and it is more demanding than many developers assume. A gap that is common, not exceptional Trials are usually designed for marketing authorisation, not for every [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pqra.gr\/el\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/\" \/>\n<meta property=\"og:site_name\" content=\"PQRA\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-26T08:07:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-26T08:24:24+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 \u03bb\u03b5\u03c0\u03c4\u03ac\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\"},\"headline\":\"Indirect Treatment Comparisons Under the EU HTA Guidelines: What Will Be Accepted\",\"datePublished\":\"2026-10-26T08:07:34+00:00\",\"dateModified\":\"2026-10-26T08:24:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\\\/\"},\"wordCount\":520,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/indirect-treatment-comparisons-eu-hta.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\\\/\",\"name\":\"Indirect Treatment Comparisons Under the EU HTA Guidelines: What Will Be Accepted - PQRA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/indirect-treatment-comparisons-eu-hta.png\",\"datePublished\":\"2026-10-26T08:07:34+00:00\",\"dateModified\":\"2026-10-26T08:24:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\\\/#breadcrumb\"},\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/indirect-treatment-comparisons-eu-hta.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/indirect-treatment-comparisons-eu-hta.png\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pqra.gr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Indirect Treatment Comparisons Under the EU HTA Guidelines: What Will Be Accepted\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"name\":\"PQRA\",\"description\":\"Your trusted partner in Pharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pqra.gr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"el\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\",\"name\":\"PQRA\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"width\":594,\"height\":362,\"caption\":\"PQRA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.pqra.gr\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Indirect Treatment Comparisons Under the EU HTA Guidelines: What Will Be Accepted - PQRA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pqra.gr\/el\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/","og_locale":"el_GR","og_type":"article","og_title":"Indirect Treatment Comparisons Under the EU HTA Guidelines: What Will Be Accepted - PQRA","og_description":"When no head-to-head trial exists, joint clinical assessment will still ask how your product compares. The methodological guidance adopted by the HTA Coordination Group sets out what evaluators expect, and it is more demanding than many developers assume. A gap that is common, not exceptional Trials are usually designed for marketing authorisation, not for every [&hellip;]","og_url":"https:\/\/www.pqra.gr\/el\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/","og_site_name":"PQRA","article_published_time":"2026-10-26T08:07:34+00:00","article_modified_time":"2026-10-26T08:24:24+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc":"admin","\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2":"3 \u03bb\u03b5\u03c0\u03c4\u03ac"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pqra.gr\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/#article","isPartOf":{"@id":"https:\/\/www.pqra.gr\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/"},"author":{"name":"admin","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c"},"headline":"Indirect Treatment Comparisons Under the EU HTA Guidelines: What Will Be Accepted","datePublished":"2026-10-26T08:07:34+00:00","dateModified":"2026-10-26T08:24:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pqra.gr\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/"},"wordCount":520,"commentCount":0,"publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"image":{"@id":"https:\/\/www.pqra.gr\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/10\/indirect-treatment-comparisons-eu-hta.png","articleSection":["Uncategorized"],"inLanguage":"el","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.pqra.gr\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.pqra.gr\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/","url":"https:\/\/www.pqra.gr\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/","name":"Indirect Treatment Comparisons Under the EU HTA Guidelines: What Will Be Accepted - PQRA","isPartOf":{"@id":"https:\/\/www.pqra.gr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pqra.gr\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/#primaryimage"},"image":{"@id":"https:\/\/www.pqra.gr\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/10\/indirect-treatment-comparisons-eu-hta.png","datePublished":"2026-10-26T08:07:34+00:00","dateModified":"2026-10-26T08:24:24+00:00","breadcrumb":{"@id":"https:\/\/www.pqra.gr\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/#breadcrumb"},"inLanguage":"el","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pqra.gr\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/"]}]},{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/#primaryimage","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/10\/indirect-treatment-comparisons-eu-hta.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/10\/indirect-treatment-comparisons-eu-hta.png","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.pqra.gr\/indirect-treatment-comparisons-under-the-eu-hta-guidelines-what-will-be-accepted\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pqra.gr\/"},{"@type":"ListItem","position":2,"name":"Indirect Treatment Comparisons Under the EU HTA Guidelines: What Will Be Accepted"}]},{"@type":"WebSite","@id":"https:\/\/www.pqra.gr\/#website","url":"https:\/\/www.pqra.gr\/","name":"PQRA","description":"Your trusted partner in Pharma","publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pqra.gr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"el"},{"@type":"Organization","@id":"https:\/\/www.pqra.gr\/#organization","name":"PQRA","url":"https:\/\/www.pqra.gr\/","logo":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","width":594,"height":362,"caption":"PQRA"},"image":{"@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c","name":"admin","image":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.pqra.gr"]}]}},"_links":{"self":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/comments?post=874"}],"version-history":[{"count":1,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/874\/revisions"}],"predecessor-version":[{"id":971,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/874\/revisions\/971"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media\/970"}],"wp:attachment":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media?parent=874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/categories?post=874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/tags?post=874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}